Catalyst Pharmaceuticals Stock In The News

CPRX Stock  USD 15.13  0.21  1.37%   
The overall news coverage of Catalyst Pharmaceuticals from major news outlets shows solid bullish sentiment on 8 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Catalyst Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Catalyst Pharmaceuticals. The specific impact of Catalyst Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Catalyst Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Catalyst Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Catalyst Pharmaceuticals Backtesting and Catalyst Pharmaceuticals Hype Analysis.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Catalyst Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
https://finance.yahoo.com/news/catalyst-pharmaceuticals-inc-nasdaq-cprx-144905668.html
 Bullish
Yahoo News
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
https://finance.yahoo.com/news/jim-cramer-10-favorite-healthcare-161824974.html
 Bullish
Investors Business Daily at Macroaxis
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years
https://finance.yahoo.com/news/investors-catalyst-pharmaceuticals-nasdaq-cprx-140030227.html
 Bullish
Yahoo News
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
https://finance.yahoo.com/news/crinetics-pharmaceuticals-crnx-stock-jumps-091400274.html
 Bullish
Yahoo News
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
https://finance.yahoo.com/news/7-biotech-stocks-ready-ride-000133276.html
 Bullish
Yahoo News
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-agamree-now-115500075.html
 Bullish
Yahoo News
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
https://finance.yahoo.com/news/catalyst-pharmaceutical-cprx-tops-q4-002002793.html
 Bullish
Yahoo News
Catalyst Pharmaceuticals Announces Publi...
https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-publication-santhera-140000469.html
 Bullish
Yahoo News
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
https://finance.yahoo.com/news/catalyst-pharmaceuticals-report-fourth-quarter-130300416.html
 Bullish
Yahoo News
Catalyst Pharmaceuticals: An Attractive Biopharma Bet
https://finance.yahoo.com/news/catalyst-pharmaceuticals-attractive-biopharma-bet-130039900.html
 Bullish

Catalyst Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Catalyst and other traded companies coverage. We help investors stay connected with Catalyst headlines for the 19th of April to make an informed investment decision based on correlating the impacts of news items on Catalyst Stock performance. Please note that trading solely based on the Catalyst Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Catalyst Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Catalyst Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Catalyst Pharmaceuticals noise-free hype analysis.
Catalyst Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Catalyst earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.

Catalyst Largest EPS Surprises

Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-09
2021-06-300.10.110.0110 
2020-11-09
2020-09-300.10.110.0110 
2020-05-11
2020-03-310.090.10.0111 
2018-11-07
2018-09-30-0.07-0.08-0.0114 
2018-08-07
2018-06-30-0.07-0.060.0114 
2017-08-09
2017-06-30-0.06-0.050.0116 
View All Earnings Estimates

Catalyst Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Catalyst Pharmaceuticals Stock. The global stock market is bearish. About 66% of major world exchanges and indexes are down. See today's market update for more information.
Yahoo News
18th of April 2024
Catalyst Pharmaceuticals, Inc. is largely controlled by institutional shareholders who own...
at finance.yahoo.com 
Investing News at Macroaxis
10th of April 2024
Catalyst Pharmaceuticals director sells 2,000 in stock
at investing.com 
Google News at Macroaxis
1st of April 2024
Catalyst Pharmaceutical Gains As Market Dips What You Should Know - Yahoo Movies Canada
at news.google.com 
Yahoo News
28th of March 2024
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Synd...
at finance.yahoo.com 
Yahoo News
27th of March 2024
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symp...
at finance.yahoo.com 
zacks News
20th of March 2024
Crinetics Pharmaceuticals Stock Jumps 19.1 percent Will It Continue to Soar
at zacks.com 
Investing News at Macroaxis
14th of March 2024
Citi sets 27 target on Catalyst Pharma stock, cites growth potential
at investing.com 
Yahoo News
13th of March 2024
Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available in the U.S. for the ...
at finance.yahoo.com 
benzinga news
14th of February 2024
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on ...
at benzinga.com 

Catalyst Pharmaceuticals Investors Sentiment

The influence of Catalyst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Catalyst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Catalyst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalyst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalyst Pharmaceuticals' short interest history, or implied volatility extrapolated from Catalyst Pharmaceuticals options trading.
When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:
Check out Catalyst Pharmaceuticals Backtesting and Catalyst Pharmaceuticals Hype Analysis.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Catalyst Stock analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.346
Earnings Share
0.63
Revenue Per Share
3.747
Quarterly Revenue Growth
0.82
Return On Assets
0.1283
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.